Several randomized controlled trials have reported distinct improvements in metabolic control (insulin sensitivity/glucose tolerance) in patients with SAS who were treated with CPAP as compared to sham-CPAP treated patients [96,97,98]. The gene discussed is INS; the disease is SATB2 associated disorder.